Literature DB >> 24512409

Rituximab-vincristine chemotherapy-induced acute anterior wall myocardial infarction with cardiogenic shock.

Ambuj Roy1, Naveen Khanna, Nagendra Boopathy Senguttuvan.   

Abstract

We present a case of an elderly man with coronary artery disease who was diagnosed with non-Hodgkin lymphoma. Soon after the administration of chemotherapy, which included rituximab and vincristine, he developed acute myocardial infarction with cardiogenic shock. The condition was managed successfully with primary percutaneous coronary intervention. We briefly discuss the possible pathogenic mechanisms of chemotherapy-induced ischemic syndrome and the management of chemotherapy in patients with high cardiovascular risk.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24512409      PMCID： PMC3967490          DOI： 10.14503/THIJ-12-2853

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN： 0730-2347


  7 in total

1.  Cardiac toxicity during rituximab administration.

Authors:  V Garypidou; V Perifanis; K Tziomalos; S Theodoridou
Journal:  Leuk Lymphoma       Date:  2004-01

2.  Rituximab induced myocardial infarction: A fatal drug reaction.

Authors:  Palamalai Arunprasath; Pakkirisamy Gobu; Biswajit Dubashi; Santhosh Satheesh; Jayaraman Balachander
Journal:  J Cancer Res Ther       Date:  2011 Jul-Sep       Impact factor: 1.805

3.  Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs.

Authors:  Igor Mikaelian; Andreas Buness; Maria-Cristina de Vera-Mudry; Charu Kanwal; Denise Coluccio; Erik Rasmussen; Hing W Char; Valerie Carvajal; Holly Hilton; Juergen Funk; Jean-Christophe Hoflack; Mark Fielden; Frank Herting; Michael Dunn; Laura Suter-Dick
Journal:  Toxicol Sci       Date:  2010-07-12       Impact factor: 4.849

4.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.

Authors:  J M Foran; A Z Rohatiner; D Cunningham; R A Popescu; P Solal-Celigny; M Ghielmini; B Coiffier; P W Johnson; C Gisselbrecht; F Reyes; J A Radford; E M Bessell; B Souleau; A Benzohra; T A Lister
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

5.  [Myocardial infarction induced by vincristine in patients with Hodgkin's lymphoma. Description of 2 cases and review of the literature].

Authors:  M Barra; M Brignole; B Sartore; A Bertulla
Journal:  G Ital Cardiol       Date:  1985-01

6.  Vincristine-induced myocardial infarction.

Authors:  E M Mandel; U Lewinski; M Djaldetti
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

7.  Acute coronary syndromes complicating the first infusion of rituximab.

Authors:  Joel D Armitage; Carlos Montero; Alisha Benner; James O Armitage; Gregory Bociek
Journal:  Clin Lymphoma Myeloma       Date:  2008-08
  7 in total
  4 in total

1.  Rituximab-Induced Acute ST Elevation Myocardial Infarction.

Authors:  Amit N Keswani; Cody Williams; Jyotsna Fuloria; Nichole M Polin; Eiman Jahangir
Journal:  Ochsner J       Date:  2015

Review 2.  Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Mauro Galeazzi; Franco Laghi-Pasini
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 3.  Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge.

Authors:  Bibhu D Mohanty; Sudipta Mohanty; Yasin Hussain; Chandrasekhar Padmaraju; Sameer Aggarwal; Rebekah Gospin; Anthony F Yu
Journal:  Future Cardiol       Date:  2017-06-01

4.  Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol.

Authors:  Luis Sánchez-Trujillo; Carlos Jerjes-Sanchez; David Rodriguez; Jathniel Panneflek; Claudia Ortiz-Ledesma; Gerardo Garcia-Rivas; Guillermo Torre-Amione
Journal:  BMJ Open       Date:  2019-03-27       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.